STERIS Toekomstige groei

Future criteriumcontroles 1/6

STERIS zal naar verwachting groeien in winst en omzet met respectievelijk 12.5% en 6.1% per jaar. De winst per aandeel zal naar verwachting groeien met 12.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12% zijn.

Belangrijke informatie

12.5%

Groei van de winst

12.5%

Groei van de winst per aandeel

Medical Equipment winstgroei17.7%
Inkomstengroei6.1%
Toekomstig rendement op eigen vermogen12.0%
Dekking van analisten

Good

Laatst bijgewerkt08 Nov 2024

Recente toekomstige groei-updates

Recent updates

What Does STERIS plc's (NYSE:STE) Share Price Indicate?

Oct 19
What Does STERIS plc's (NYSE:STE) Share Price Indicate?

Is STERIS (NYSE:STE) A Risky Investment?

Oct 01
Is STERIS (NYSE:STE) A Risky Investment?

Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued

Sep 16

Earnings Tell The Story For STERIS plc (NYSE:STE)

Sep 13
Earnings Tell The Story For STERIS plc (NYSE:STE)

Steris: Q2 Numbers Solidify Buy Thesis

Aug 13

STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price

Aug 08
STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price

When Should You Buy STERIS plc (NYSE:STE)?

Jul 04
When Should You Buy STERIS plc (NYSE:STE)?

Is STERIS (NYSE:STE) Using Too Much Debt?

Jun 13
Is STERIS (NYSE:STE) Using Too Much Debt?

Steris: Moving On, Losing Its Teeth

Apr 14

STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 31% Above Its Share Price

Mar 29
STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 31% Above Its Share Price

STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet

Mar 07
STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet

Steris: Strong Healthcare Products Growth Coupled With Weak AST Business

Feb 17

STERIS plc's (NYSE:STE) Business Is Trailing The Industry But Its Shares Aren't

Feb 15
STERIS plc's (NYSE:STE) Business Is Trailing The Industry But Its Shares Aren't

An Intrinsic Calculation For STERIS plc (NYSE:STE) Suggests It's 23% Undervalued

Dec 17
An Intrinsic Calculation For STERIS plc (NYSE:STE) Suggests It's 23% Undervalued

Should You Investigate STERIS plc (NYSE:STE) At US$203?

Nov 24
Should You Investigate STERIS plc (NYSE:STE) At US$203?

Steris: Comprehensive Sterilization Portfolios Tailored To Procedure Volumes

Nov 08

We Think STERIS (NYSE:STE) Can Stay On Top Of Its Debt

Nov 06
We Think STERIS (NYSE:STE) Can Stay On Top Of Its Debt

Are STERIS plc (NYSE:STE) Investors Paying Above The Intrinsic Value?

Sep 18
Are STERIS plc (NYSE:STE) Investors Paying Above The Intrinsic Value?

Steris: Remains On Track For Strong Fiscal '24, Added Upsides From Operating Leverage

Sep 01

When Should You Buy STERIS plc (NYSE:STE)?

Aug 10
When Should You Buy STERIS plc (NYSE:STE)?

Steris: Continuing To Grow The Product Lineup

Jun 20

Steris falls 10% on Q3 revenue, profit miss, 2023 profit guidance lowered

Feb 09

Steris declares $0.47 dividend

Feb 01

These 4 Measures Indicate That STERIS (NYSE:STE) Is Using Debt Reasonably Well

Feb 01
These 4 Measures Indicate That STERIS (NYSE:STE) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of STERIS plc (NYSE:STE)

Dec 28
Calculating The Intrinsic Value Of STERIS plc (NYSE:STE)

Steris declares $0.47 dividend

Nov 02

STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly

Nov 01
STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly

Steris: Non-GAAP Valuations Supportive Of Substantial Upside

Sep 04

STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.47

Aug 18
STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.47

STERIS' (NYSE:STE) Dividend Will Be Increased To $0.47

Aug 04
STERIS' (NYSE:STE) Dividend Will Be Increased To $0.47

Steris Non-GAAP EPS of $1.90 in-line, revenue of $1.2B misses by $20M

Aug 02

Winst- en omzetgroeiprognoses

NYSE:STE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/20276,2128841,2781,6906
3/31/20265,8437881,1041,3289
3/31/20255,4946737981,0999
9/30/20245,3265916801,101N/A
6/30/20245,235561594996N/A
3/31/20245,139551613973N/A
12/31/20234,8851,024594934N/A
9/30/20234,7051,007535849N/A
6/30/20234,563576494806N/A
3/31/20234,536557395757N/A
12/31/20224,784-28349713N/A
9/30/20224,777-8399752N/A
6/30/20224,773377472819N/A
3/31/20224,223285397685N/A
12/31/20214,248279412701N/A
9/30/20213,848250400662N/A
6/30/20213,407286424653N/A
3/31/20213,108397450690N/A
12/31/20203,057433476701N/A
9/30/20203,022424400627N/A
6/30/20203,003413384615N/A
3/31/20203,031408376591N/A
12/31/20192,976393340570N/A
9/30/20192,898336347573N/A
6/30/20192,840319336548N/A
3/31/20192,782304350540N/A
12/31/20182,730269325490N/A
9/30/20182,696316314467N/A
6/30/20182,651303N/A478N/A
3/31/20182,620291N/A458N/A
12/31/20172,585243N/A463N/A
9/30/20172,570144N/A453N/A
6/30/20172,582120N/A424N/A
3/31/20172,613110N/A424N/A
12/31/20162,616142N/A439N/A
9/30/20162,588167N/A364N/A
6/30/20162,431135N/A294N/A
3/31/20162,233111N/A255N/A
12/31/20152,04294N/A185N/A
9/30/20151,897113N/A221N/A
6/30/20151,870135N/A241N/A
3/31/20151,842135N/A246N/A
12/31/20141,807133N/A233N/A
9/30/20141,739123N/A234N/A
6/30/20141,660122N/A223N/A
3/31/20141,615129N/A210N/A
12/31/20131,585132N/A189N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei STE ( 12.5% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van STE ( 12.5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.6% per jaar).

Hoge groeiwinsten: De winst van STE zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van STE ( 6.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van STE ( 6.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen STE zal naar verwachting over 3 jaar laag zijn ( 12 %).


Ontdek groeibedrijven